Strontium Ranelate

摘要

Postmenopausal osteoporosis is a major public health problem. The objective of treatment is to either follow anti-resorptive or bone forming strategies (1). Currently available medications, such as bisphosphonates, selective estrogen receptor modulators, and teriparatides, have shown their ability to reduce vertebral and/or nonvertebral fractures. But it remains sub-optimal. There is, therefore, an urgent need of new effective, safe, and user-friendly medications to optimize the treatment of postmenopausal osteoporosis. Among these recent advances strontium ranelate(Sr) has gained importance in the treatment and prevention of osteoporosis (2).